Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today’s lower share price an opportunity?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businessman planning and analyst investment marketing data.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

The GSK (LSE:GSK) share price has fallen off its perch. So it may be a good time to research and consider the stock opportunity.

I think the global biopharma company has been dripping with promise for a while and looks like a growth-focused proposition for its shareholders. 

A pipeline of R&D hopefuls

The business has ambitions to deliver operational progress via its research and development (R&D) efforts. So could it go on to perform like its peer AstraZeneca has done over the past decade or so? Maybe.

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL6 Apr 20204 Apr 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '2520212021202220222023202320242024202520256k8k10k12k14kwww.fool.co.uk

GSK’s news flow has been gathering pace. It’s common for the company to release positive updates about its drugs and treatments under development.

However, unlike AstraZeneca, the firm has yet to gain sufficient progress from commercialising new drugs. Yet it may hit upon some bestsellers ahead, and incoming cash flow could start to increase. My hope is such operational progress will push the stock higher.

Here’s what the share price chart looks like.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

For the time being, GSK is still working through legacy issues. For example, in October the directors announced an agreement to pay out up $2.27bn in settlement of US litigation cases.

The arrangement should deal with about 93% of the well-reported legal proceedings relating to the firm’s old heartburn medication Zantac. So the move will put a big part of the problem behind the business, allowing it to move on.

The growth agenda is unaffected

It’s an expensive outcome. But the company said it can fund the costs of the settlements from existing resources. That means there will be no change to the growth agenda or investment plans for R&D.

Such legal battles are not unusual for companies the size of GSK. When I read the notes at the bottom of the financial reports of big firms from various sectors, the list of ongoing legal issues is often long.

Many types of business operations can be risky, and legal activity is often part of what it takes to keep things progressing. Nevertheless, one of the specific uncertainties for GSK shareholders is that some other drug in its stable may attract litigation.

Another risk is the firm’s R&D pipeline may disappoint and fail to produce any big-selling medicines.

Nevertheless, chief executive Emma Walmsley was upbeat in October’s third-quarter results report. The R&D pipeline is strengthening and there have been 11 positive phase-three trials so far in 2024. On top of that, the company plans five new “product approval opportunities” next year.

A positive outlook and dividends now

The directors are sticking to previous guidance for 2024 and Walmsley is “even more confident” about the outlook for next year onwards.

Meanwhile, City analysts expect normalised earnings to advance by around 11% this year and about 8% in 2025. 

But one of the main things I like about GSK is the decent shareholder dividend. With the share price near 1,333p, the forward-looking yield for 2025 is around 4.8%.

Given the potential for multi-year growth in the business, I reckon that level of yield suggests a keen valuation here that’s worth investors considering.

But there may be an even bigger investment opportunity that’s caught my eye:

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Stack of British pound coins falling on list of share prices
Investing Articles

Why hasn’t its 9.9% yield boosted the Phoenix share price?

Phoenix Group has a dividend close to double digits, but saw a weak share price performance in recent years. Christopher…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

With average 10% yields, these mid-cap FTSE shares could supercharge a passive income portfolio

Some of the best passive income gems can be found on the UK's smaller indexes like the FTSE 250 and…

Read more »

A coin being dropped into a piggy bank
Investing Articles

As the Barclays share price tanks 19% in 2 days, is this a great buying opportunity?

As a trade war sends the Barclays share price into a tailspin, Andrew Mackie steps back to look at the…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is Fundsmith Equity still a good choice for a Stocks and Shares ISA in 2025?

Many Britons hold the Fundsmith Equity fund in their Stocks and Shares ISAs. Is this still a good move? Edward…

Read more »

Investing Articles

Nvidia stock is down 24% this year. Time to buy the dip?

Christopher Ruane has been eyeing Nvidia stock as a potential addition to his portfolio for a while. Is a recent…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Down 25% since January, this resilient dividend stock’s catching my eye

Maintaining the UK’s rail, water, and energy infrastructure isn’t the most exciting business. But it has made this a solid…

Read more »

Investing Articles

Prediction: Unilever to outperform the FTSE 100 over the next 12 months

The FTSE 100 has made a strong start to 2025, but Stephen Wright thinks a popular dividend stock could be…

Read more »

Investing Articles

I just bought this legendary S&P 500 tech stock for my ISA, 27% off its highs

This S&P 500 stock has tanked over the last month and Edward Sheldon has snapped it up for his portfolio…

Read more »